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with an average of 97.3% (see Figure 1 for an example of pass-rate vs. 
gantry angle result). Using this method, a problem with the gantry 
motor control with one linac at our centre was found, which was 
corroborated (albeit at a much higher time cost) by commercial VMAT 
QA products, further proving its utility in a clinical setting. 
 
 
Figure 1. Chi results comparing EPID images to predicted images for 
each sub-arc during a complete VMAT delivery. 
 
Conclusions: The method provides a comprehensive and highly 
efficient pre-treatment verification of VMAT delivery using EPID. Dose 
delivery accuracy is assessed as a function of gantry angle to ensure 
accurate treatment. Individual Chi maps for small sub-arcs provide a 
useful tool for error diagnostics.  
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Purpose/Objective: In volumetric-modulated arc therapy (VMAT) 
gantry speed, multileaf collimator configuration, and dose rate vary 
continuously during delivery. For a safe clinical implementation of 
VMAT, accurate 3D dose verification is essential but also complicated. 
In our department, EPID-based in vivo dosimetry using a semi-
empirical back-projection model is clinically employed to verify all 
VMAT treatments. The purpose of this study was to investigate the 
sensitivity of our 3D in vivo EPID dosimetry approach to detecting 
patient-related errors during VMAT delivery. 
Materials and Methods: Treatment planning of VMAT was performed 
using the SmartArc module of the Pinnacle treatment planning 
system. In order to assess the sensitivity of our EPID-based in vivo 
dosimetry method, patient-related errors were simulated by changing 
position and dimension of an anthropomorphic (Alderson) phantom. 
The phantom was irradiated using a 2-arc head-and-neck (6 MV), 
prostate (10 MV) and lung (10MV) VMAT technique. The errors 
comprised a vertical and horizontal phantom shift of 2 cm, a 10 
degree rotation, and the addition of 1cm tissue-equivalent material. 
Dose distributions reconstructed from EPID images and the original 
planned dose distributions were compared using 3D γ evaluation using 
3% dose difference relative to the maximum dose, and 3 mm distance-
to-agreement as criteria.  
Results: Table 1 shows the 3D gamma evaluation of the total dose 
relative to the situation without errors. For the prostate treatment, 
the effect of the introduced errors is negligible, except that the 
reconstructed dose at the prescription point was 4.2% higher for a 
change in thickness of 1 cm. For the head-and-neck treatment, results 
for the gamma evaluation showed a larger sensitivity for the 
introduced errors. Also the dose difference at isocenter for the 
thickness error was larger: -7.8%. The results for the lung plan were 
similar to those for the prostate plan. 
 
 
 
 
 
 
 
 
 
 
Table 1. Gamma Evaluation Results (3%, ±3mm) and Relative Dose 
Differences at Isocenter for Introduced Errors 
Treatment 
Site  Error Type  γmean γ1% 
γ 
≤1(%)  
Relative Dose Difference 
at Isocenter(%)  
Prostate  
Vertical shift 0.41 1.2 96.7  0.8  
Horizontal 
shift  0.30 0.8 99.9  0.4  
Rotation  0.30 0.9 99.5  0.6  
Thickness  0.66 1.4 86.9  -4.2  
Head-and- 
Neck  
Vertical shift 0.90 3.8 69.6  1.1  
Horizontal 
shift  2.23 8.3 36.1  5.1  
Rotation  0.77 3.9 77.5  -1.2  
Thickness  0.81 2.5 72.1  -7.8  
Lung  
Vertical shift 0.42 1.2 97.4  -0.7  
Horizontal 
shift  0.35 1.0 98.9  -1.2  
Rotation  0.49 1.8 92.7  0.1  
Thickness  0.59 1.5 91.9  -7.0 
 
Conclusions: Our verification results show that vertical and horizontal 
shifts and a rotation of the order of 2cm and 10 degree, respectively, 
do not result in significant deviations between EPID reconstructed and 
treatment plan dose distributions for both prostate and lung VMAT 
treatments. The head-and-neck VMAT treatments are more sensitive 
for position errors. With VMAT, EPID dosimetry is often not able to 
detect patient position discrepancies, and should be combined with 
IGRT. However, changes in patient thickness are easily detected.  
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Purpose/Objective: For in vivo verification of IMRT and VMAT 
treatments a 3D dose reconstruction method based on EPID dosimetry 
is routinely applied in our clinic. After reconstruction, the in vivo dose 
is compared to the planned dose by means of a 3D γ analysis. 
Although this method is capable of detecting treatment deviations, 
the clinical relevance of γ parameters is far from obvious. Therefore, 
we wish to correlate the 3D γ evaluation results with other, clinically 
more common parameters used to determine the quality of a dose 
distribution, such as DVH and EUD parameters for specific regions of 
interest (ROIs). As a pilot study, head-and-neck (H&N) VMAT 
treatments were investigated. 
Materials and Methods: 18 treatments were selected having a variety 
of deviations in the in vivo dose, combined with a few treatments 
showing no deviations. For 56 fractions of these treatments, the 3D in 
vivo dose distribution was reconstructed. Several parameters were 
calculated for three different ROIs: the PTV, the volume enclosed by 
the 50% isodose surface and the volume enclosed by the 30% isodose 
surface minus the PTV. These ROIs were chosen to be representative 
for our current clinical portal dosimetry evaluation, and to clearly 
separate high- and low-dose regions. The calculated γ parameters 
were the γ pass rate, 99th percentile of the γ-distribution (γ1%) and 
the mean γ value. Differences between planned and reconstructed 
dose distributions were next evaluated for each ROI using DVH 
parameters D1, D50 and D99 and EUD(1), i.e., the mean dose and 
EUD(7), i.e., focusing on hot spots. Since γ values carry no sign, 
correlations between absolute deviations of DVH and EUD parameters 
and γ parameters were evaluated. 
Results: The table shows the obtained correlation coefficients. For all 
ROIs, strong correlations are observed between γ1%, mean γ and DVH 
and EUD parameters. The D99 parameters, however, hardly correlated 
with anything, except weakly with parameters of the 50% and 30%-PTV 
ROIs. 
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ROI γ 
parameter 
|D1EPID 
– 
D1plan| 
(%pt) 
|D50EPID 
– 
D50plan| 
(%pt) 
|D99EPID 
– 
D99plan| 
(%pt) 
|EUD(1)EPID 
/ 
EUD(1)plan| 
(%) 
|EUD(7)EPID 
/ 
EUD(7)plan| 
(%) 
PTV pass rate -0.68 -0.92 0.25 -0.92 -0.91 
PTV γ1% 0.95 0.84 -0.04 0.87 0.89 
PTV mean-γ 0.85 0.97 -0.15 0.98 0.98 
30%-
PTV 
pass rate 
-0.79 -0.85 -0.41 -0.83 -0.80 
30%-
PTV 
γ1% 
0.68 0.85 0.76 0.83 0.75 
30%-
PTV 
mean-γ 
0.95 0.98 0.32 0.99 0.98 
50% pass rate -0.79 -0.73 -0.50 -0.74 -0.76 
50% γ1% 0.99 0.99 0.84 0.99 0.99 
50% mean-γ 0.96 0.99 0.88 0.99 0.98 
 
Conclusions: 3D γ parameters of the in vivo dose distributions are 
highly correlated with DVH and EUD parameters. The lack of 
correlation with the D99 is logical since underdosages are hardly ever 
observed in the PTV of in vivo dose distributions for H&N VMAT 
treatments.  
These results indicate that γ criteria from in vivo dose evaluation that 
have a clinical relevance in terms of DVH and EUD parameters can 
readily be obtained. This pilot study paves the way for moving from 
hard-to-interpret γ-analysis results to the clinically more common and 
relevant DVH and EUD parameters. This will provide radiation 
oncologists with more insight in the clinical relevance of observed 
deviations during in vivo dosimetry. 
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Purpose/Objective: Pre-treatment quality assurance of radiotherapy 
plans is an essential check of the treatment planning system (TPS) 
dose calculation, as well as the plan transfer to the linear 
accelerator. With increasing numbers of complex treatments – 
including volumetric modulated arc therapy (VMAT) – the burden of 
individual linac-based QA has implications for workflow. In this work 
we introduce an automated Monte Carlo verification system for VMAT 
treatments, with the aim of reducing or replacing linac 
measurements. The system allows dose statistics to be reported for 
individual ROIs, and is able to accept plans exported from a record-
and-verify system, allowing a two-way check of plan transfer. 
Materials and Methods: The verification system is triggered when 
DICOM-RT format files (plan, CT, structures and dose) are exported 
from a TPS. The system automatically prepares and reformats the files 
into instructions for Monte Carlo simulation using GATE/GEANT4. 
Calculations on the patient’s CT dataset are then scheduled on a 44 
CPU cluster. The outputs are automatically merged and gamma 
analysis performed against the planned dose distribution.  
In order to validate the Monte Carlo model, comparisons were made 
to water tank measurements for depth-dose curves, profiles and 
output factors. Further validation was performed by delivering 5 
prostate and 5 head and neck VMAT plans to a cylindrical phantom 
(Delta4), and comparing the results to Monte Carlo simulations of the 
same geometry. To demonstrate the potential of the system for 
routine use, a prostate and head and neck VMAT patient were verified 
and their results interpreted. 
 
 
Results: The model showed good agreement against water tank 
measurements, with >95% of points passing a 2%/2mm gamma analysis 
for depth-dose curves at a range of field sizes. Validation of the VMAT 
simulation against the Delta4 gave results consistent with our 
accepted tolerance for pre-treatment QA, with pass rates of 98.6 (± 
0.9) % for the prostates and 95.8 (± 2.6) % for the head and necks at 
the 3%/3mm gamma level. 
Full dosimetric verification on a patients CT data took the system 10-
12 hours on the present computing cluster, in order to achieve < 2% 
uncertainty within the 5 % isodose volume. By setting up verification 
‘templates’ for individual sites, it was possible to report the gamma 
passes for various relevant ROIs within prostate and head and neck 
plans.  
Conclusions: An automated Monte Carlo verification system has been 
developed which allows for accurate, independent dose calculations 
on the patient CT dataset. ROI-specific results can be reported. 
Export is also allowed from a record-and-verify system to check plan 
transfer. This system demonstrates that highly complex plan QA can 
be performed using a software solution, allowing for the possibility of 
reducing or replacing machine-based measurements. Work is now 
being done to determine tolerances for the calculations, and 
expansion of the cluster is underway to meet clinical demands.  
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Purpose/Objective: In our institution, every clinical IMPT field must 
be verified before the delivery of the first fraction. Since 2007, when 
the new cyclotron was introduced into clinical practice, 2,528 IMPT 
fields have been verified. The purpose of this study was to analyze the 
results of all these fields and to decide whether patient specific 
verifications are necessary in the future. 
Materials and Methods: The treatment planning system automatically 
generates a steering file per field of each plan containing the 
information about selected Bragg peaks, their position and weights. 
Dosimetric verification of every steering file then consists of a 
measurement of two orthogonal profiles using an ionization chamber 
array consisting of two arms of thirteen ionization chambers each at a 
single depth in water. This is mounted on an automatically controlled 
water column such that measurements at different depths can be 
performed as required. The measured profiles are directly sent to the 
treatment planning system where they are compared with the 
predicted doses.  
Results: A summary of the results is shown in figure 1. The analysis of 
all verified IMPT fields have shown that more than 96% of verified 
fields were within our defined tolerances. There were no systematic 
errors in the position of the beam in relation to the isocenter or for 
the range in water. In addition, the precision (SD), calculated over all 
fields, is within ± 0.8 mm (SD) in all three directions. In the absolute 
dose, we have an accuracy of about 0.6 % of the predicted dose and 
precision of ±1.30 %. Although a small number of verifications were 
out of tolerance, most of these were due to problems with the 
measurement itself, e.g. chamber / water column calibration 
problems, malfunctioning ionisation chambers or bad cable 
connections. 
